

Ferenc G Rick

List of Publications by Citations

Source: <https://exaly.com/author-pdf/741438/ferenc-g-rick-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

1,540
citations

23
h-index

35
g-index

62
ext. papers

1,691
ext. citations

5.1
avg. IF

4.15
L-index

#	Paper	IF	Citations
60	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1 β mediated metabolic switch. <i>Oncogene</i> , 2014 , 33, 5251-61	9.2	149
59	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 2604-9	11.5	78
58	LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. <i>Prostate</i> , 2011 , 71, 736-47	4.2	59
57	Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3755-60	11.5	59
56	Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 1655-60	11.5	54
55	Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 559-63	11.5	48
54	The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 183-191	2.8	44
53	Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. <i>Peptides</i> , 2014 , 52, 104-12	3.8	44
52	Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2084-9	11.5	44
51	Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6102-12	5.6	44
50	Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. <i>Oncotarget</i> , 2012 , 3, 988-97	3.3	38
49	Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 1084-9	11.5	35
48	An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. <i>OncoTargets and Therapy</i> , 2013 , 6, 391-402	4.4	34
47	GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. <i>Cell Cycle</i> , 2009 , 8, 3149-56	4.7	32
46	Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. <i>Journal of Urology</i> , 2012 , 187, 1498-504	2.5	30
45	Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. <i>Peptides</i> , 2017 , 89, 60-70	3.8	29
44	Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. <i>Aging</i> , 2012 , 4, 755-67	5.6	29

43	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. <i>Oncotarget</i> , 2012 , 3, 686-99	3.3	29
42	Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. <i>Prostate</i> , 2008 , 68, 1763-72	4.2	28
41	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 14513-8	11.5	28
40	Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. <i>Prostate</i> , 2012 , 72, 555-65	4.2	26
39	Targeting the 5TAMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 617-32	6.4	24
38	Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 270-4	2.8	23
37	Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. <i>Oncology Reports</i> , 2013 , 30, 413-8	3.5	23
36	Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 1359-1364	11.5	22
35	Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. <i>Cell Cycle</i> , 2014 , 13, 2790-7	4.7	22
34	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 2617-22	11.5	22
33	Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. <i>Oncotarget</i> , 2014 , 5, 4567-78	3.3	22
32	Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis. <i>Prostate</i> , 2018 , 78, 970-980	4.2	22
31	Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. <i>Prostate</i> , 2013 , 73, 873-83	4.2	21
30	A correlation of endocrine and anticancer effects of some antagonists of GHRH. <i>Peptides</i> , 2010 , 31, 1839-46	3.46	21
29	Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. <i>Toxins</i> , 2013 , 5, 1244-60	4.9	20
28	Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. <i>Cancer Letters</i> , 2010 , 294, 35-42	9.9	20
27	Agonists of luteinizing hormone-releasing hormone in prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2237-47	4	19
26	Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. <i>Cell Cycle</i> , 2012 , 11, 2518-25	4.7	19

25	Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. <i>Oncotarget</i> , 2013 , 4, 422-32	3.3	19
24	Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. <i>Prostate</i> , 2017 , 77, 1036-1054	4.2	18
23	The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. <i>Hormone and Metabolic Research</i> , 2010 , 42, 781-6	3.1	18
22	GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. <i>Cell Cycle</i> , 2012 , 11, 4203-10	4.7	17
21	Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. <i>Anti-Cancer Drugs</i> , 2009 , 20, 553-8	2.4	17
20	Hormonal manipulation of benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , 2013 , 23, 17-24	2.8	15
19	Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. <i>Anti-Cancer Drugs</i> , 2013 , 24, 150-7	2.4	15
18	Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. <i>Peptides</i> , 2009 , 30, 1643-50	3.8	15
17	New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. <i>Oncotarget</i> , 2015 , 6, 9728-39	3.3	15
16	Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. <i>Frontiers in Physiology</i> , 2014 , 5, 259	4.6	14
15	Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. <i>Oncotarget</i> , 2013 , 4, 751-60	3.3	14
14	Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. <i>Targeted Oncology</i> , 2013 , 8, 281-90	5	13
13	Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. <i>Hormone and Metabolic Research</i> , 2011 , 43, 816-20	3.1	13
12	Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study. <i>Oncoscience</i> , 2014 , 1, 665-73	0.8	13
11	The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. <i>International Journal of Oncology</i> , 2011 , 39, 1025-32	4.4	11
10	Potential of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 781-6	11.5	10
9	Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1895-900	11.5	9
8	Potentiating effects of GHRH analogs on the response to chemotherapy. <i>Cell Cycle</i> , 2015 , 14, 699-704	4.7	8

7	New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. <i>Asian Journal of Andrology</i> , 2015 , 17, 925-8	2.8	7
6	A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. <i>British Journal of Haematology</i> , 2018 , 181, 476-485	4.5	5
5	Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. <i>Anti-Cancer Drugs</i> , 2012 , 23, 906-13	2.4	5
4	Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. <i>Hormones and Cancer</i> , 2015 , 6, 100-6	5	4
3	Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis. <i>Journal of Radiation Oncology</i> , 2012 , 1, 389-396	0.7	4
2	Re: editorial comment on LHRH antagonist cetorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747). <i>Journal of Urology</i> , 2013 , 189, 1604-5	2.5	
1	Grade-dependent Response to Finasteride in Early Prostate Cancer. <i>EBioMedicine</i> , 2016 , 7, 13-4	8.8	